Britain Set to Become First Country to Approve Three-Parent IVF

Parliament voted to allow mitochondrial replacement therapy last year. This latest decision suggests we may see babies born from the technique in the country in 2017.

Written byJoshua A. Krisch
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PIXABAY, DRKONTOGIANNNIIVFOn Thursday (December 16), Britain’s Human Fertilisation and Embryology Authority agreed to approve mitochondrial replacement therapy in humans. The technique is informally known as “three-parent” in vitro fertilization (IVF), because it is intended to prevent genetic disorders by using DNA from the mother, the father, and a female mitochondrial donor.

“Mitochondrial donation offers a real opportunity to cure a class of potentially devastating inherited conditions and will bring hope to hundreds of affected families in the UK,” Dagan Wells, a professor at Oxford University, told Reuters. These inherited conditions include muscular dystrophy and organ failure.

Clinics in Britain will still need to apply to a governmental fertility regulator for permission to use the technique on a case-by-case basis, STAT News reported, but the move will still put Britain far ahead of the United States, where the procedure is still illegal. In September, U.S. doctors traveled to Mexico to test the technique, which produced the first baby from the three-parent IVF procedure.

Mary Herbert of Newcastle University told STAT that her hospital plans to apply for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies